Byrne Ailish Katherine, Twohig Helen, Muller Sara, Scott Ian C
Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
Haywood Academic Rheumatology Centre, Haywood Hospital, Midlands Partnership University NHS Foundation Trust, High Lane, Burslem, Staffordshire, UK.
Prim Health Care Res Dev. 2025 May 7;26:e42. doi: 10.1017/S1463423625000362.
A crucial step towards improving the care of people with fibromyalgia is understanding current practice. Our systematic review aims to address this by synthesising the global evidence around healthcare use in people with fibromyalgia, including its variation across groups of people, geographical locations, and over time.
Fibromyalgia is a chronic condition characterized by widespread pain alongside a broad range of non-pain symptoms. Its substantial impact on peoples' lives and high prevalence mean that ensuring people with fibromyalgia receive evidence-based and appropriate care is a clinical and research priority. Whilst guidelines recommend that people with fibromyalgia receive a prompt diagnosis, care that focuses on non-pharmacological interventions, and in many countries should be predominantly managed in the community, existing evidence indicates they often wait many years for a diagnosis, commonly receive long-term opioid medicines, and see multiple hospital specialists.
Relevant databases will be searched, with 25% of screening, data extraction, and quality appraisal conducted by two reviewers. Eligible studies will have evaluated healthcare use in adults with fibromyalgia using data obtained from electronic health record, registry, or insurance databases (providing generalizable findings in large, representative datasets). Data will be synthesized using meta-analysis and/or synthesis without meta-analysis where possible.
By providing an in-depth analysis of healthcare use and its variation in people with fibromyalgia, the results from this systematic review could be used to benchmark practice, inform targeted management strategies to those with the highest levels of healthcare use (and therefore care need), and provide insight into whether certain countries require specific guideline/policy changes.
改善纤维肌痛患者护理的关键一步是了解当前的实践情况。我们的系统评价旨在通过综合全球范围内有关纤维肌痛患者医疗保健使用情况的证据来解决这一问题,包括不同人群、地理位置以及不同时间的差异。
纤维肌痛是一种慢性疾病,其特征是广泛疼痛并伴有多种非疼痛症状。它对人们生活的重大影响以及高患病率意味着确保纤维肌痛患者获得循证且适当的护理是临床和研究的重点。虽然指南建议纤维肌痛患者应得到及时诊断,护理应侧重于非药物干预,并且在许多国家主要应在社区进行管理,但现有证据表明,他们往往要等待多年才能得到诊断,通常会长期服用阿片类药物,并且会看多个医院专科医生。
将检索相关数据库,由两名评审员进行25%的筛选、数据提取和质量评估。符合条件的研究将使用从电子健康记录、登记册或保险数据库中获得的数据评估成年纤维肌痛患者的医疗保健使用情况(在大型代表性数据集中提供可推广的结果)。数据将尽可能使用荟萃分析和/或非荟萃分析进行综合。
通过对纤维肌痛患者的医疗保健使用情况及其差异进行深入分析,本系统评价的结果可用于规范实践,为医疗保健使用水平最高(因此护理需求也最高)的人群提供有针对性的管理策略,并深入了解某些国家是否需要进行特定的指南/政策调整。